Please use this identifier to cite or link to this item:
https://repositorio.ufba.br/handle/ri/15680
metadata.dc.type: | Artigo de Periódico |
Title: | Ascorbic Acid Has Superior Ex Vivo Antiproliferative, Cell Death-Inducing and Immunomodulatory Effects over IFN-α in HTLV-1-Associated Myelopathy |
Other Titles: | PLoS Medicine |
Authors: | Moens, Britta Decanine, Daniele Menezes, Soraya Maria Cunha, Antônio Ricardo Khouri Santos, Gilvanéia Silva Lopez, Giovanni Alvarez, Carolina Talledo, Michael Gotuzzo, Eduardo Kruschewsky, Ramon de Almeida Castro, Bernardo Galvão Vandamme, Anne Mieke Weyenbergh, Johan Van |
metadata.dc.creator: | Moens, Britta Decanine, Daniele Menezes, Soraya Maria Cunha, Antônio Ricardo Khouri Santos, Gilvanéia Silva Lopez, Giovanni Alvarez, Carolina Talledo, Michael Gotuzzo, Eduardo Kruschewsky, Ramon de Almeida Castro, Bernardo Galvão Vandamme, Anne Mieke Weyenbergh, Johan Van |
Abstract: | Background Clear therapeutic guidelines for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) are missing due to the lack of randomized double-blind controlled clinical trials. Moderate yet similar clinical benefit has been demonstrated for IFN-α and high-dose ascorbic acid (AA) monotherapy in a large open clinical trial. However, there is a lack of in vivo and in vitro studies exploring and comparing the effects of high-dose AA and IFN-α treatment in the context of HAM/TSP. Therefore, we performed the first comparative analysis of the ex vivo and in vitro molecular and cellular mechanisms of action of IFN-α and high-dose AA in HAM/TSP. Principal Findings Through thymidine incorporation and quantification of Th1/Th2/Th17 cytokines, we demonstrate that high-dose AA displays differential and superior antiproliferative and immunomodulatory effects over IFN-α in HAM/TSP PBMCs ex vivo. In addition, high-dose AA, but not IFN-α, induced cell death in both HAM/TSP PBMCs and HTLV-1-infected T-cell lines MT-2 and MT-4. Microarray data combined with pathway analysis of MT-2 cells revealed AA-induced regulation of genes associated with cell death, including miR-155. Since miR-155 has recently been demonstrated to up-regulate IFN-γ, this microRNA might represent a novel therapeutic target in HAM/TSP, as recently demonstrated in multiple sclerosis, another neuroinflammatory disease. On the other hand, IFN-α selectively up-regulated antiviral and immune-related genes. Conclusions In comparison to IFN-α, high-dose AA treatment has superior ex vivo and in vitro cell death-inducing, antiproliferative and immunomodulatory anti-HTLV-1 effects. Differential pathway activation by both drugs opens up avenues for targeted treatment in specific patient subsets. |
metadata.dc.rights: | Acesso Aberto |
URI: | http://repositorio.ufba.br/ri/handle/ri/15680 |
Issue Date: | Jul-2012 |
Appears in Collections: | Artigo Publicado em Periódico (Faculdade de Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Ricardo Khouri.pdf | 712,94 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.